Navigation Links
Cancer wasting due in part to tumor factors that block muscle repair, study shows
Date:10/23/2013

COLUMBUS, Ohio A new study reveals that tumors release factors into the bloodstream that inhibit the repair of damaged muscle fibers, and that this contributes to muscle loss during cancer wasting. The condition, also called cancer cachexia, accompanies certain types of cancer, causes life-threatening loss of body weight and lean muscle mass, and is responsible for up to one-in-four cancer deaths. There is no treatment for the condition.

The study was led by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James), and it points to new strategies and new drug targets for treating cancer cachexia.

The findings were published in the Journal of Clinical Investigation.

The researchers looked at muscle stem cells, which are also called satellite cells. These cells are associated with muscle fibers and are essential for repairing damaged fibers. Normally, damage to muscle fibers causes these stem cells to proliferate and to differentiate into mature muscle cells. These muscle cells then fuse with damaged surrounding fibers to limit muscle wasting. This process is blocked during cancer cachexia, the researchers say.

"Our study showed that although muscle stem cells are activated during cachexia, factors released by the tumor block these cells from differentiating into muscle cells, which leaves them unable to repair cachectic muscle fibers," says principal investigator Denis Guttridge, PhD, professor of molecular virology, immunology and medical genetics and a member of the OSUCCC James Molecular Biology and Cancer Genetics Program.

"By identifying agents that overcome the block and allow muscle stem cells to differentiate, it might be possible to restore muscle mass and enhance the quality of life of cancer patients with cachexia," he says.

For this study, Guttridge and his colleagues used animal models and tissue from cachectic pancreatic-cancer patients to identify factors in the muscle microenvironment that contribute to cancer cachexia. Key findings include:

  • Cachexia is associated with tumor-induced damage to skeletal muscle cells and tumor-induced proliferation of muscle stem cells;
  • Overexpression of the muscle stem cell factor, Pax7, blocks the cells' ability to differentiate and promotes cancer-induced wasting;
  • The overexpression of Pax7 promotes cancer wasting by blocking the maturation of muscle cells and their fusion with surrounding fibers, which allows muscle to gain mass;
  • The overexpression of Pax7 is controlled by NF-kappa B (NF-kB), which has been shown to play multiple roles in cancer. In cachexia, NF-kB causes the deregulation of Pax7 expression, which in turn impairs differentiation of muscle progenitor cells and promotes muscle atrophy;
  • Because of its tissue specificity, Pax7 inhibition might offer an attractive therapy for cancer cachexia.

"For decades, studies in cachexia have focused on mechanisms that lead to muscle wasting from within skeletal muscle fibers," Guttridge says. "Our study is the first to show proof of concept that events occurring outside the muscle fiber and within the muscle microenvironment also play a part in driving muscle wasting in cancer."


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Wexner Medical Center
Source:Eurekalert

Related medicine news :

1. Neurotoxin effectively relieves bone cancer pain in dogs, Penn researchers find
2. A simple test may catch early pancreatic cancer
3. Imaging breast cancer with light
4. Fred Hutchinson Cancer Research Center opens HIV-vaccine lab in South Africa
5. Mount Sinai finds value and limitations of patient assistance programs for women with breast cancer
6. Like a Celebrity Concierge Brings Fun to the Fight with #ShopForACure Breast Cancer Charity Shopping Soiree at Copia NYC
7. Mount Sinai Researchers Find Value -- and Limitations -- of Patient Assistance Programs for Women with Breast Cancer
8. Airelle Skin Participates in Long Island Breast Cancer Awareness Event
9. Internet users more likely to engage in cancer-preventive behaviors
10. Study Examines Connections Between Depression and Breast Cancer, Allsup Reports
11. Rapid method to detect BRAF mutations in cancer tissue samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality ... 40th Anniversary of ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. ... not only to the association, but also to the Health Care Quality and Patient ...
(Date:3/23/2017)... ... March 23, 2017 , ... The founders of Dr. ... as winners of American Dreams & Good Housekeeping Seal Initiative, a nationwide search ... and Good Housekeeping. , Steven Wang, MD ., a renowned dermatologist and ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
(Date:3/23/2017)... Rey, CA (PRWEB) , ... March 23, 2017 ... ... its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st annual Compliance ... optimizes and accelerates the coding audit process for all medical chart types with ...
(Date:3/23/2017)... ... , ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous ... Bonetta Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures ... Rose‘s new book presents actual events in the life of her family, which validate ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... , March 23, 2017   Casetabs , the ... native mobile app for the iPhone. With this new ... coordination and communication for physician offices, ambulatory surgery centers ... app offers iPhone users even faster, more reliable access ... it even easier to connect care teams so that ...
Breaking Medicine Technology: